AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $100.23
- 52-wk high
- $122.20
- High
- $101.77
- 52-wk low
- $74.50
- Low
- $99.83
- Prev close
- $101.80
- Mkt cap
- $6.98B
- Volume
- 482.3K
- Fwd P/E
- 555.6x
- Beta
- 1.97
- P/S
- 29.1x
- P/B
- 68.7x
- Profit margin
- -85.6%
- Op margin
- -68.1%
- ROE
- -117.1%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 9.9% above what analysts expected.
Earnings per share
-$0.81 expected
Reports Nov 3, 2026, in 54 days
EPS expected
-$0.84 to -$0.67
Revenue expected
14 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $51.3M | $57.3M | $60.1M | $71.3M |
| Cost of what it sold | $5.5M | $4.8M | $7.2M | $8.9M |
| Gross profit | $45.8M | $52.5M | $53.0M | $62.3M |
| What it spent | ||||
| Research and development | $46.0M | $42.0M | $41.7M | $43.4M |
| Sales and admin | $52.4M | $57.5M | $63.6M | $67.4M |
| Total operating expenses | $98.5M | $99.5M | $105.3M | $110.9M |
| What was left | ||||
| Operating profit | -$52.7M | -$47.1M | -$52.4M | -$48.6M |
| Interest on debt | $4.7M | $4.6M | $4.6M | $4.5M |
| Profit before tax | -$52.8M | -$47.5M | -$55.1M | -$48.9M |
| Tax | $111.0K | -$31.0K | $545.0K | $444.0K |
| Net profit | -$52.9M | -$47.5M | -$55.6M | -$49.3M |
| EBITDA | -$47.7M | -$42.6M | -$50.3M | -$44.1M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
An AI drug specialist zeroes in on rare forms of obesity
NeutralSep 3Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today
BullishAug 31Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target
Leans bullishAug 28Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run
Leans bearishAug 26Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story
BullishAug 26Rhythm's Imcivree becomes first approved therapy for acquired hypothalamic obesity in Japan
BullishAug 25Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE®
BullishAug 25
Macro
10 macro signals shaping RYTM right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results